Idrofos 50mg Tablet is a pharmaceutical preparation containing IBANDRONIC ACID as its active ingredient, classified under the Supportive Care general category and the Supportive Care speciality domain. Ibandronic Acid is a bisphosphonate that inhibits osteoclast activity, reducing bone breakdown and helping to prevent skeletal complications from bone metastases and treating high blood calcium levels associated with cancer. Manufactured by SUN PHARMACEUTICAL INDUSTRIES LTD. As with any medicine, dosage and treatment duration must be individualised by the treating specialist based on the patient's diagnosis, disease stage, organ function, and concurrent medications.

Uses of Idrofos 50mg Tablet
Used in the treatment of bone metastases from breast cancer and to manage cancer-related hypercalcaemia.

Idrofos 50mg Tablet containing IBANDRONIC ACID works as described: Ibandronic Acid is a bisphosphonate that inhibits osteoclast activity, reducing bone breakdown and helping to prevent skeletal complications from bone metastases and treating high blood calcium levels associated with cancer. Therapeutically, it is classified under the Supportive Care category and Supportive Care speciality domain. Regular monitoring by the treating specialist is recommended to assess treatment response and manage side effects.

• Always inform your doctor about every medicine, supplement, or herbal product you are currently taking before starting Idrofos 50mg Tablet. Inform your dentist about ibandronic acid treatment before any dental procedures; caution with other nephrotoxic drugs.

Idrofos 50mg Tablet is available under medical guidance and should be used strictly as advised by a licensed specialist. Storage: Store below 30°C in a dry place, away from direct light. Disposal: Do not flush unused product or dispose of it in household waste; return unused or expired product to a licensed pharmacy. Manufactured by SUN PHARMACEUTICAL INDUSTRIES LTD and complies with applicable regulatory standards.